Detection of BCR/ABL Translocation in Bone Marrow Derived Mesenchymal Stem Cells in Egyptian CML Patients
DOI:
https://doi.org/10.3889/oamjms.2015.040Keywords:
Chronic myeloid leukemia, mesenchymal stem cell, Philadelphia chromosomeAbstract
BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells. It is characterized at the cytogenetic level by Philadelphia (ph) chromosome and at the molecular level by the BCR/ABL gene rearrangement. Bone marrow derived mesenchymal stem cells (MSCs) are pluripotent stem cells that can differentiate into several mesenchymal tissues.
AIM: To observe the biological characteristics of MSCS from CML patients and to determine whether MSCs harbor the abnormal BCR/ABL translocation similar to CML bone marrow cells.
SUBJECTS AND METHODS: Characterized MSCs were isolated from 12 newly diagnosed Philadelphia positive untreated CML patients.
RESULTS: MSCs can be readily isolated from CML marrow and exhibit major expansion. Flow cytometry analysis revealed the typical MSC phenotype. Moreover; MSCs do not harbor the BCR/ABL translocation confirmed by karyotype and real time PCR.
CONCLUSION: MSCs from CML patients express the typical MSC phenotype; and do not express the BCR/ABL gene. Since; MSCs are able to support engraftment of hematopoietic stem cells in stem cell transplantation(SCT) as well as suppress alloreactive T cells causing graft versus –host disease, this current study provides evidence that in a SCT setting of CML patients, autologous MSCs could be a source of stem cell support in future cell therapy applications.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Shumakov VI, Onishchenko NA, Rasulov MF, Krasheninnikov ME, Zaidenov VA. Mesenchymal bone marrow stem cells more effectively stimulate regeneration of deep burn wounds than embryonic fibroblasts. Bull Exp Biol Med. 2003;136(2):192-5. DOI: https://doi.org/10.1023/A:1026387411627
Jootar S, Pornprasertsud N, Petvises S, Rerkamnuaychoke B, Disthabanchong S, Pakakasama S, Ungkanont A, Hongeng S. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion. Leuk Res. 2006;30(12):1493-8. DOI: https://doi.org/10.1016/j.leukres.2006.04.013
Takahashi N, Miura I, Saitoh K, Miura AB. Lineage involvement of stem cells bearing the Philadelphia in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence activated cell sorting and fluorescence in situ hybridization. Blood. 1998;92(2): 4758-4763. DOI: https://doi.org/10.1182/blood.V92.12.4758.424k35_4758_4763
Gunsilius E, Duba HC, Petzer AL, Kahler CM, Grunewald K, Stockhammer G, Gabl C, Dirnhofer S, Clausen J, Gasil G. Evidence from a leukemia model for maintenance of vascular endothelium by bone marrow –derived endothelial cells. Lancet. 2000;355(9216): 1688-1691. DOI: https://doi.org/10.1016/S0140-6736(00)02241-8
Fang B, Zheng C, Liao L, Han Q, Sun Z, Jiang X and Zhao RC. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood. 2005; 105(7):2733-2740. DOI: https://doi.org/10.1182/blood-2004-07-2514
Wὃhrer S., Rabitschi W., Shehata M. et al. Mesenchymal Stem Cells in patients with chronic myelogenous leukemia or BI-phenotypic Ph+ acute leukemia are not related to leukemic clone. Anticancer Research. 2007;27:3837-3842.
Aschan J. Allogeneic hematopoietic stem cell transplantation: current status and future outlook. British Medical Bulletin. 2006; 77-78(1): 23-36. DOI: https://doi.org/10.1093/bmb/ldl005
Carrara RCV, Orellana MD, Fonteset AM et al. Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant. Brazilian Journal of Medical and Biological Research. 2007; 40(1):57-67. DOI: https://doi.org/10.1590/S0100-879X2007000100008
Zhao Z, Tang X, You Y, et al. Assessment of bone marrow mesenchymal stem cell biological characteristics and support hematopoiesis function in patients with chronic myeloid leukemia. Leukemia Research. 2006; 30(8): 993-1003. DOI: https://doi.org/10.1016/j.leukres.2005.12.010
Kern S, Eichler H, Stoeve J, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24(5): 1294-1301. DOI: https://doi.org/10.1634/stemcells.2005-0342
Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. Managed Care Pharmacy. 2007; 13(8A):8-12. DOI: https://doi.org/10.18553/jmcp.2007.13.s8-a.8
Van der Geest IMM, Sablik KA. Is there a clonal relationship between leukemia cells and bone marrow mesenchymal stem cell? Erasmus Journal of Medicine. 2011; 2(1): 20-23.
Sato K, Ozaki K, Mori M. et al. Mesenchymal Stromal Cells for Graft –Versus-Host Disease: Basic and Clinical Outcomes. Journal of Clinical and Experimental Hematopathology. 2010; 50(2):79-89. DOI: https://doi.org/10.3960/jslrt.50.79
Shin CH, Nien JC, Shie LH. et al. Isolation and characterization of size-sieved stem cells from human bone marrow. Stem Cells. 2002; 20(1): 249-258. DOI: https://doi.org/10.1634/stemcells.20-3-249
Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel jagged-2 dependent regulatory dendritic cell population. Blood. 2009; 113(1):46-57. DOI: https://doi.org/10.1182/blood-2008-04-154138
Bhatia R, McGlave PB, Dewald GW, et al. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood. 1995; 85(12):3636-3645. DOI: https://doi.org/10.1182/blood.V85.12.3636.bloodjournal85123636
Weisberg E, Manley PW, Cowan–Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia . Nature Reviews Cancer. 2007; 7(5):345-356. DOI: https://doi.org/10.1038/nrc2126
Jabbour E, Cortes JE, Giles FJ, et al. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007; 109(11): 2171-2181. DOI: https://doi.org/10.1002/cncr.22661
Gambacrti-Passerini C, Antolini L, MahoN F, et al. Multicenter Independent Assessment of Outcomes in chronic myeloid leukemia patients treated with Imatinib. National cancer Institute. 2010; 103(7):553-561. DOI: https://doi.org/10.1093/jnci/djr060
Li T, Wu Y. Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche. Bone Marrow Research. 2011; 3:1-8. DOI: https://doi.org/10.1155/2011/353878
Lazarus HM, Koe ON, Devine SM, et al. Co=transplantation of HLA-identical sibling culture –expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology of blood and marrow transplantation. 2005; 11(5):389-398. DOI: https://doi.org/10.1016/j.bbmt.2005.02.001
Xishan Z, Guangyu A, Yuguang S, et al. The research on the immuno-modulatory defect of mesenchymal stem cell from chronic myeloid leukemia patients. Experimental Clinical Cancer Research. 2011; 30(1):47. DOI: https://doi.org/10.1186/1756-9966-30-47
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
